2019 Parkinson Study Group Symposium and Training

2019年帕金森研究组研讨会及培训

基本信息

项目摘要

Abstract The proposed three-year conference project, centered on the annual clinical research symposium of the Parkinson Study Group (PSG) and associated annual meeting activities, will foster the education and training of early stage investigators to ensure that the highest quality translational and clinical research continues to be conducted toward improved therapy for Parkinson's and related neurological disease. This project goal will be achieved through two specific aims (SAs). In SA #1, the PSG will present its “32nd Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders” in collaboration with the Huntington Study Group (HSG), Dystonia Study Group (DSG), Tourette Syndrome Study Group (TSSG), Cooperative Ataxia Group (CAG), and Tremor Research Group (TRG) on Saturday, April 6, 2019 in Phoenix, AZ, and the 33rd and 34th symposia annually thereafter. The peer-reviewed program includes both platform and poster presentations in a live format with audience participation. The symposia themes will authoritatively address major challenges and opportunities in pursuit of improved treatment for people with Parkinson's and other neurodegenerative diseases, with keynote talks conveying complementary neurobiological, clinical development and patient perspectives. The 2019 Symposium will cover the revolutionary impact of PD genetics, and GBA and LRRK2 mutations in particularly, on PD therapeutics development. SA #2 is designed to provide early-stage clinical investigators with movement disorders training a multi-faceted practical orientation to PD clinical research. The selected junior investigators will participate in several novel and interactive, educational research activities in addition to the symposium, including a) direct exchange with experienced patient advocates of the Parkinson's Foundation's PAIR (Parkinson's Advocates in Research) program to learn how patient input can benefit their research, and b) the PSG Mentoring Committee's junior investigator skills workshop with annually rotating themes spanning clinical research project development, grant proposal writing, and emerging research methodologies. Junior investigators completing participation in the project will be substantially better prepared and motivated to pursue careers and rigorous studies in clinical neurology.
摘要 拟议的为期三年的会议项目,以美国医学会的年度临床研究研讨会为中心 帕金森研究小组(PSG)和相关的年度会议活动,将促进教育和 培训早期研究人员,以确保最高质量的翻译和临床研究 继续为改善帕金森氏症和相关神经疾病的治疗而进行。 该项目目标将通过两个具体目标(SA)来实现。在SA#1中,PSG将展示其 第32届帕金森氏病的病因、发病机制和治疗年会 其他运动障碍“,与亨廷顿研究小组(HSG)合作,Dystonia研究 抽动症研究组(TSSG)、协作性共济失调组(CAG)和震颤 研究小组(TRG)于2019年4月6日星期六在亚利桑那州凤凰城举行第33届和第34届研讨会 此后每年一次。同行评审计划包括现场平台演示和海报演示 采用受众参与的格式。研讨会主题将有力地应对重大挑战。 以及寻求改善帕金森氏症和其他疾病患者治疗的机会 神经退行性疾病,主旨演讲传达补充神经生物学,临床 发展和病人的观点。2019年研讨会将讨论PD的革命性影响 遗传学,特别是GBA和LRRK2突变,与PD治疗的发展有关。SA#2是 旨在为早期临床研究人员提供运动障碍的多方面培训 对帕金森病临床研究的实用导向。选定的初级调查人员将参与几项 除研讨会外,开展新颖和互动的教育研究活动,包括a)直接 与帕金森基金会(Parkinson‘s Foundation)有经验的患者倡导者交流 研究倡导者)计划,以了解患者的意见如何有助于他们的研究,以及b)PSG 指导委员会的初级研究员技能研讨会,每年轮换主题跨越临床 研究项目开发、拨款提案撰写和新兴研究方法。朱尼尔 完成参与该项目的调查人员将得到更好的准备和动力 在临床神经学方面追求事业和严谨的研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL A SCHWARZSCHILD其他文献

MICHAEL A SCHWARZSCHILD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL A SCHWARZSCHILD', 18)}}的其他基金

Planning for Prevention of Parkinson's Disease: a trial design forum
帕金森病预防规划:试验设计论坛
  • 批准号:
    10827547
  • 财政年份:
    2023
  • 资助金额:
    $ 2.5万
  • 项目类别:
Urate-LRRK2 interactions in Parkinson's disease
尿酸盐-LRRK2在帕金森病中的相互作用
  • 批准号:
    10427325
  • 财政年份:
    2019
  • 资助金额:
    $ 2.5万
  • 项目类别:
Urate-LRRK2 interactions in Parkinson's disease
尿酸盐-LRRK2在帕金森病中的相互作用
  • 批准号:
    9978147
  • 财政年份:
    2019
  • 资助金额:
    $ 2.5万
  • 项目类别:
Urate-LRRK2 interactions in Parkinson's disease
尿酸盐-LRRK2在帕金森病中的相互作用
  • 批准号:
    10640903
  • 财政年份:
    2019
  • 资助金额:
    $ 2.5万
  • 项目类别:
Urate-LRRK2 interactions in Parkinson's disease
尿酸盐-LRRK2在帕金森病中的相互作用
  • 批准号:
    10210454
  • 财政年份:
    2019
  • 资助金额:
    $ 2.5万
  • 项目类别:
2019 Parkinson Study Group Symposium and Training
2019年帕金森研究组研讨会及培训
  • 批准号:
    9890023
  • 财政年份:
    2019
  • 资助金额:
    $ 2.5万
  • 项目类别:
2017 Parkinson Study Group Symposium and Training
2017年帕金森研究组研讨会及培训
  • 批准号:
    9398499
  • 财政年份:
    2017
  • 资助金额:
    $ 2.5万
  • 项目类别:
Phase 3 trial of inosine for Parkinson's disease CCC
肌苷治疗帕金森病 CCC 的 3 期试验
  • 批准号:
    9292399
  • 财政年份:
    2015
  • 资助金额:
    $ 2.5万
  • 项目类别:
Phase 3 trial of inosine for Parkinson's disease CCC
肌苷治疗帕金森病 CCC 的 3 期试验
  • 批准号:
    9258571
  • 财政年份:
    2015
  • 资助金额:
    $ 2.5万
  • 项目类别:
Phase 3 trial of inosine for Parkinson's disease CCC
肌苷治疗帕金森病 CCC 的 3 期试验
  • 批准号:
    9129755
  • 财政年份:
    2015
  • 资助金额:
    $ 2.5万
  • 项目类别:

相似海外基金

Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
  • 批准号:
    10760051
  • 财政年份:
    2023
  • 资助金额:
    $ 2.5万
  • 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
  • 批准号:
    2303692
  • 财政年份:
    2023
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
  • 批准号:
    468168
  • 财政年份:
    2022
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10427960
  • 财政年份:
    2022
  • 资助金额:
    $ 2.5万
  • 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
  • 批准号:
    10577074
  • 财政年份:
    2022
  • 资助金额:
    $ 2.5万
  • 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
  • 批准号:
    486588
  • 财政年份:
    2022
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
  • 批准号:
    2760091
  • 财政年份:
    2022
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10621188
  • 财政年份:
    2022
  • 资助金额:
    $ 2.5万
  • 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
  • 批准号:
    10891016
  • 财政年份:
    2021
  • 资助金额:
    $ 2.5万
  • 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
  • 批准号:
    10230365
  • 财政年份:
    2020
  • 资助金额:
    $ 2.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了